From GlobeNewswire: 2025-02-27 04:43:00

The global market for Direct-to-Consumer Genetic Testing is projected to grow from $2.3 billion in 2024 to $3.7 billion by 2029, with a 10.0% CAGR. This report covers major companies, products, and trends in segments like ancestry, health, and lifestyle, with technologies such as genotyping and genome sequencing included.

Direct-to-consumer pharmacogenetic testing helps identify the best medications for individuals based on their genetics, reducing the risk of adverse effects. Factors driving market growth include increased access to genetic testing, aggressive marketing, preference for pharmacogenomic testing, and the growing prevalence of chronic diseases like cancer and diabetes.

The global DTC genetic testing market is projected to reach $3.7 billion by the end of 2029, with a CAGR of 10.0% during the forecast period. The market is mainly driven by people’s curiosity about their ancestry and desire for personalized health insights to assess disease risk and make informed decisions.

The DTC genetic testing market is segmented by application type, technology type, and geographic region, with the ancestry segment expected to dominate in 2029. North America holds the largest share of the market. Leading companies in the market include 23andme Inc., Ancestry, Color Health Inc., and others.

For further information or to purchase a copy of the report from BCC Research, contact [email protected]. BCC Research provides objective market research reports to help readers make informed business decisions without noise or hype.



Read more at GlobeNewswire: DTC Genetic Testing Market Set to Grow at 10% CAGR Through